BioMarin Pharmaceutical Inc. Common Stock (BMRN)
Stock · NASDAQ · Health Care
$54.71as of 10/16/2026
Price chart
Active signals
Support level
$53.89
Industry
Biotechnology: Pharmaceutical Preparations
BMRN Signal Track Record
How signals performed across all stocks →What BMRN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +2.3% | 57% | September 18, 2026 |
| Bollinger Band Breakdown | 25 | +1.4% | 52% | September 23, 2026 |
| Bollinger Band Breakout | 22 | -1.5% | 41% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 19 | +2.1% | 53% | October 1, 2026 |
| Any 20-session window (baseline) | -0.6% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal st…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3,221
- Website
- www.biomarin.com/
Fundamentals
- 1-day range
- $54.44$56.53
- Market cap
- $11.88B
- P/E (trailing)
- 151.14
- P/E (forward)
- 8.24
- EPS (trailing)
- $0.36
- Dividend yield
- —
- Beta
- 0.23
- Avg. volume
- 2.14M
52-week range
$49.26$70.98
Next earnings: October 26, 2026 · EPS estimate $0.87After Closeconfirmed
How BioMarin Pharmaceutical Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Gross Profit$2.50B(78%)
Operating Income$409.48M(13%)
Forecasts
27 analyst ratings
Buy 77%
Hold 23%
Sell 0%
1-year price forecast
High
$124
+126.6%
Median
$90
+64.5%
Low
$60
+9.7%
BioMarin Pharmaceutical Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$449.74▼ 2.19%Market cap $11.79BP/E —$393.61$615
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.79B | — | $449.74 | ▼ 2.19% | $393.61$615 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114benzinga · 10/14/2026
- Is Vertex Stock Worth More Than Its Competitors?Yahoo · 10/9/2026
- BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual MeetingYahoo · 10/9/2026
- BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction GrowthBenzinga · 10/9/2026
- BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?Yahoo · 10/8/2026
- FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingYahoo · 10/7/2026
- BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55 Unfavorable Impact To GAAP And Non-Gaap Diluted EPS For FY26Benzinga · 10/6/2026
- BioMarin Appoints Cara Bauer as Chief People OfficerYahoo · 10/5/2026
- BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual CongressYahoo · 10/2/2026
Insider Activity
Insider Actions →Acquired
73.5K
Disposed
27.2K
- Gregory R. Friberg · September 30, 2026 · Tax Withholding4.1K @ $60
- Robert M. Plenge · September 10, 2026 · Grant6.1K
- George Eric Davis · September 2, 2026 · Sale17.6K @ $66.28
- Athena Countouriotis · June 2, 2026 · Grant7.5K
- Timothy P. Walbert · June 2, 2026 · Grant7.5K
- Maykin Ho · June 2, 2026 · Grant7.5K
- Robert J. Hombach · June 2, 2026 · Grant7.5K
- Mark J. Enyedy · June 2, 2026 · Grant7.5K
- Willard H. Dere · June 2, 2026 · Grant7.5K
- Ian T. Clark · June 2, 2026 · Grant7.5K
- Barbara W. Bodem · June 2, 2026 · Grant7.5K
- Elizabeth M. Anderson · June 2, 2026 · Grant7.5K
- Cristin Hubbard · May 20, 2026 · Tax Withholding2.3K @ $50.2
- Gregory R. Friberg · May 7, 2026 · Sale3.3K @ $53.85
Institutional Ownership
March 31, 2026
- Total shares held
- 175.70M
- Total value held
- $9.68B
- Institutional holders
- 545
Top holders this quarter
- Unknown19.82M
- Unknown14.56M
- Unknown14.19M
- Unknown8.64M
- Unknown7.68M
- Unknown7.30M
- Unknown7.06M
- Unknown4.70M
- Unknown3.82M
- Unknown3.80M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.